|Bid||5.05 x 100|
|Ask||6.30 x 400|
|Day's Range||6.25 - 6.35|
|52 Week Range||3.56 - 7.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.60|
“We are very pleased to initiate enrollment of our CIDS Phase 3 study in the U.S., providing the opportunity to U.S. burn experts to treat pediatric patients with NexoBrid,” said Gal Cohen, President and Chief Executive Officer of MediWound. “The current management of pediatric burns requires intensive medical therapy and typically several traumatic surgical procedures to remove eschar and prevent secondary complications.
MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has completed enrollment in NexoBrid® U.S. Phase 3 DETECT study. “We are happy to achieve this important milestone of completing the enrollment in NexoBrid Phase 3 study, which is one of the most comprehensive randomized controlled studies ever conducted in burn care, and we believe it will support our Biological License Application (BLA) submission to the FDA,” said Gal Cohen, president and chief executive officer of MediWound. The DETECT study is a prospective, controlled, multi-national, assessor-blinded Phase 3 study with 175 patients randomized to be treated with either NexoBrid, gel vehicle or standard-of-care, in a ratio of 3-to-1-to-3, with follow-up periods at 12 months and at 24 months.
MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced receipt of authorization from the Ministry of Health in South Korea to market and distribute NexoBrid® for the removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns. This regulatory approval builds upon NexoBrid’s marketing authorization from the European Medicines Agency (EMA) for the same indication and validates MediWound’s strategy of using the EMA approved registration file for seeking approval in international markets.
MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that following a meeting with the U.S. Food and Drug Administration (FDA), the Agency agreed that MediWound’s development plan for NexoBrid for the debridement of skin injuries inflicted by Sulfur Mustard (a chemical warfare agent, typically dispersed as a fine mist of liquid droplets) in adults and children, would be in accordance with the Animal Rule, as it is neither ethical nor feasible to conduct human trials with chemical warfare agents.
On a per-share basis, the Yavne, Israel-based company said it had a loss of 17 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Anticipates completion of enrollment of Phase 3 DETECT Study of NexoBrid ® around mid-2018. Conference call begins today at 8:30 a.m. Eastern Time. YAVNE, Israel, May 10, 2018-- MediWound Ltd., a fully-integrated ...
MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the first quarter ended March 31, 2018 at 7:00 am Eastern time on Thursday, May 10, 2018. Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. Eastern time to discuss the financial results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-289-0438 (in the U.S.) 1809 212 883 (Israel), or 323-794-2423 (outside the U.S. & Israel) and entering passcode 370010.
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal ...
The Yavne, Israel-based company said it had a loss of 9 cents per share. Losses, adjusted to account for discontinued operations, came to 8 cents per share. The results topped Wall Street expectations. ...
NEW YORK, NY / ACCESSWIRE / March 19, 2018 / MediWound Ltd. (NASDAQ: MDWD ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at 8:30 AM Eastern Time. To ...
On a per-share basis, the Yavne, Israel-based company said it had a loss of 49 cents. Losses, adjusted to account for discontinued operations, were 16 cents per share. The results exceeded Wall Street ...
If you are looking to invest in MediWound Ltd’s (NASDAQ:MDWD), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...